Fuji Pharma Co., Ltd.

Tokyo Stock Exchange 4554.T

Fuji Pharma Co., Ltd. Operating Income Margin for the year ending September 30, 2024: 8.41%

Fuji Pharma Co., Ltd. Operating Income Margin is 8.41% for the year ending September 30, 2024, a -10.87% change year over year. Operating Income Ratio is the proportion of a company's operating income to its net sales, measuring the efficiency of its core business operations in generating profits.

Fuji Pharma Co., Ltd. Operating Income Margin for the year ending September 30, 2023 was 9.44%, a -11.50% change year over year.
Fuji Pharma Co., Ltd. Operating Income Margin for the year ending September 30, 2022 was 10.66%, a 8.21% change year over year.
Fuji Pharma Co., Ltd. Operating Income Margin for the year ending September 30, 2021 was 9.85%, a 6.07% change year over year.
Fuji Pharma Co., Ltd. Operating Income Margin for the year ending September 30, 2020 was 9.29%, a -19.24% change year over year.

Key data

Date	Operating Income Margin	EBT Margin	Net Income Margin	EBITDA Margin

Tokyo Stock Exchange: 4554.T

Fuji Pharma Co., Ltd.

CEO	Mr. Toyoyuki Kamide
IPO Date	Feb. 22, 2010
Location	Japan
Headquarters	5-7 Sanban-cho
Employees	1,621
Sector	Health Care
Industries Pharmaceuticals

Description

Fuji Pharma Co., Ltd. engages in the research and development, manufacture, and marketing of pharmaceutical products in Japan and internationally. The company offers injection agents, internal drugs, drugs for external use, and diagnostic products. It also provides medical care for women; in vitro diagnostics, acute medical care products, and curative medicines; and information regarding pharmaceuticals and health. Fuji Pharma Co., Ltd. was incorporated in 1965 and is headquartered in Tokyo, Japan.

Key trends

Past 5 years